Cancer’s conversions

A developmental transition may be a useful model for tumor progression.

Written byNancy Gavert and Avri Ben-Ze ev
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Until recently, the universally accepted dogma in cancer research stated that replicating cells accumulate several rounds of mutations before becoming cancerous. According to that dogma, the mutations that result in metastatic spread throughout the body occur late in tumor progression. This idea has recently been challenged by the identification of cancer stem cells (CSCs), which provide a new explanation for both the initiation and propagation of tumorigenesis. Rather than following a linear process that starts with unchecked replication and ends with the loss of adhesion molecules that drives metastasis, CSCs can self-renew, proliferate, differentiate, and even revert back to a stem cell state, producing metastatic cells at unexpected stages of the disease.

With a new understanding that cancer progression does not necessarily follow a particular order, researchers have been looking for models to help explain how and when cancers become aggressive. While the idea of CSCs helps explain some observations ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies